Kolexia
Bignon Anne Laure
Gastro-entérologie
Hôpital Côte de Nacre
Caen, France
35 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Tumeurs du pancréas Carcinomes Cellules tumorales circulantes Instabilité des microsatellites Carcinome à cellules en bague à chaton Tumeurs neuroendocrines Adénocarcinome

Industries

Ipsen
10 collaboration(s)
Dernière en 2022
Servier
6 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2020
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

PANOPTIMOX: Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   18 août 2022
Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.
2022 ASCO Annual Meeting I   02 juin 2022
LuLu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.
European journal of nuclear medicine and molecular imaging   06 mai 2022
Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival - a registry-based study.
BMC health services research   01 octobre 2021
Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   09 août 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   21 juillet 2021
CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
British journal of cancer   10 juin 2021
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
The oncologist   02 octobre 2019
Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial).
2019 Gastrointestinal Cancers Symposium   29 janvier 2019
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts.
HPB : the official journal of the International Hepato Pancreato Biliary Association   20 novembre 2018